EMNIFY
20.2.2024 15:01:33 CET | Business Wire | Press release
Today, emnify, the leader in cloud-native IoT connectivity solutions, announces the general availability of the industry’s first converged cellular and satellite IoT connectivity on a single emnify IoT eSIM. SuperNetwork SatPlus is offered as part of the emnify SuperNetwork, the leading IoT cellular connectivity service providing multi-network coverage in over 180 countries.
The SuperNetwork SatPlus package combines emnify’s IoT-dedicated cellular access with Skylo’s non-terrestrial network (NTN) satellite service, enabling IoT device manufacturers, OEMs and application and solution providers to add a new level of service enabled by seamless, satellite connectivity failover for devices outside of, or disconnected from, cellular coverage.
SuperNetwork SatPlus opens up a whole new level of IoT connectivity availability for use cases in asset tracking, fleet management, building safety and security, agriculture, and more. IoT businesses can now differentiate their product and service experience and drive their top line revenues by offering a premium level of data connectivity service: ubiquitous coverage even in the most remote areas.
How SuperNetwork SatPlus works
emnify IoT SuperNetwork SatPlus is available in selected European countries and the USA and includes 10MB of cellular connectivity combined with options for 10, 30 or 60 satellite messages per month. With SatPlus, SuperNetwork customers have the security of ubiquitous, uninterrupted IoT connectivity, with seamless switching to satellite networks as devices leave cellular coverage regions. This converged offering is designed for customers that require high availability and a failover solution to be assured that critical application data, such as a high value asset’s position, will always be transmitted.
By enabling both cellular and satellite network access from a single eSIM, single management platform, and single radio module, SatPlus uplevels customer experience and drives down hardware and connectivity costs as it reduces operational overhead associated with adding satellite connectivity.
“Businesses around the world have had to contend with interruptions in their operations and services due to limited terrestrial network infrastructure and rollouts. Bringing together satellite and cellular coverage as a network of networks fills in the blank spaces on the terrestrial coverage map and provides an additional layer of connectivity backup. emnify is excited to be the first to commercially offer this enhanced level of truly global connectivity as part of the expanding emnify IoT SuperNetwork,” said Frank Stoecker, CEO and emnify Co-Founder.
“We are excited to accelerate the availability of the industry’s first converged NTN satellite and cellular connectivity offering through our partnership with emnify,” said Tarun Gupta, CPO and Co-Founder, Skylo. “By delivering satellite and cellular connectivity in a single service, we’re helping IoT businesses increase the reliability and reduce the complexity of IoT connectivity, with a single provider, billing plan, and hardware configuration.”
emnify partners up with leading providers of purpose-built hardware
SatPlus is compatible with market-leading, affordable, converged hardware modules from Murata and IoT chipsets from Sony Semiconductor Israel (Sony), conforming with standard form factors and suitable for a variety of device sizes and designs.
“Designed for cellular IoT applications, the ALT1250 is engineered for devices which prioritize battery life, small size, and global coverage. The 4G/5G LPWA chipset supports 2G, CAT-M, NB-IoT and NB NTN connectivity options and is built to meet the needs of IoT device manufacturers looking to provide new levels of uptime and global coverage across business-critical use cases,” said Dima Feldman, VP Product Management and Marketing at Sony Semiconductor Israel. “Our collaboration with emnify, Murata and Skylo takes our vision forward, enabling IoT devices to connect everywhere.”
Module provider Murata is offering the Type 1SC radio module evaluation board including antenna and application development kit compatible with the SuperNetwork SatPlus service.
“The Type 1SC radio module combined with the Sony ALT1250 chipset and the emnify IoT eSIM provides a compact, low cost, CAT-M & NB-IoT module for a new breed of devices that support both cellular and satellite network protocols to provide global coverage for any type of device,” said Hirokazu Nakae, General Manager, Connectivity Module Product Department at Murata.
Customers interested in getting started with SuperNetwork SatPlus can learn more here. SuperNetwork SatPlus will be generally available in June 2024.
Meet emnify at Mobile World Congress, Barcelona
emnify will be at MWC Barcelona, February 26th to 29th. You can find us at the Berlin Mobile booth in Hall 7 Stand 7B81, or in meeting room 7G70MR. To discuss SuperNetwork SatPlus or any other IoT connectivity requirements, book a meeting: https://www.emnify.com/events/mwc-barcelona
About emnify
emnify is the leading cloud building block for cellular communications in the IoT stack, connecting millions of IoT devices globally – from electric vehicles to energy meters, alarm systems to GPS trackers, thermometers to health wearables. The emnify API and SIM technology connect and secure any kind of IoT deployment to its application back-end. emnify’s cloud-native integrations and no-code workflows ensure seamless lifecycle scalability for deployments of all sizes – from local start-up to global enterprise. The award-winning emnify IoT SuperNetwork is the largest globally distributed mobile cloud core network of its kind, supporting local network access (2G – 5G, LTE-M, NB-IoT and satellite) in over 180 countries from more than 25 cloud regions – and counting. emnify’s solution is built on partnerships with the leading hyperscale cloud service providers, system integrators, and hundreds of network operators worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220129205/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom